Overview

• Early-phase studies published in The Lancet and presented at the American Diabetes Association’s Scientific Sessions showed that weekly injections of amycretin achieved up to 24.3% weight loss over 36 weeks while daily oral doses resulted in 13.1% loss after 12 weeks.
• Amycretin combines GLP-1 receptor agonism with amylin receptor targeting to regulate blood sugar levels and suppress appetite.
• Reported side effects were mainly mild to moderate gastrointestinal symptoms such as nausea and vomiting that generally resolved by the end of treatment.
• Novo Nordisk plans to launch a Phase 3 amycretin programme in the first quarter of 2026 ahead of regulatory review.
• The availability of a pill formulation could reduce the burden on healthcare systems and expand access to weight-loss therapy as UK GPs prepare to prescribe GLP-1 treatments next week.